SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as its price experiences a significant drop, sparking intense debate within the community over whether this signals further capitulation or presents a prime "buy the dip" opportunity amid discussions of market manipulation and forced liquidations.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Intense community debate surrounds Ethereum as a broader crypto market downturn triggers liquidations, with participants sharply divided between panic selling and aggressively buying the dip while also criticizing previous bullish price targets. This volatility persists despite ongoing institutional inflows and increased staking activity, though some attribute the price action to market manipulation.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid a broad crypto market decline, driven by controversial claims linking Bitcoin to the Epstein files and anticipation of Ripple's token unlocks and US regulatory developments. The community remains divided between those expressing panic over price drops and others seizing the opportunity to "buy the dip," confident in XRP's long-term utility and eventual institutional adoption.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending amidst a significant crypto market downturn, polarizing community sentiment between panic and 'buy the dip' opportunities, even as the ecosystem sees sustained institutional interest and robust network usage challenged by a recent lawsuit against its foundation.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano ($ADA) is trending due to a significant price drop, sparking widespread fear and accusations of it being a 'scam' or 'rugpull' among frustrated investors; however, a strong community faction views this dip as a 'buy opportunity' for long-term gains, believing it's a deliberate 'shakeout' before a major altcoin rally.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amidst deeply divided market sentiment, with many investors reporting significant losses and fearing further declines, while a persistent contingent remains optimistic, actively buying dips and anticipating future recovery. The community is broadly debating whether the current crypto downturn is a deeper bear market or a temporary correction before an eventual rebound, often recalling past influencer-driven price movements.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is trending with high volatility as the community speculates on an expected announcement around February 1st, prompting many to "buy the dip" in anticipation of significant gains. However, this bullish sentiment is heavily contested by warnings of a pump-and-dump meme coin, with widespread concerns about its legitimacy and multiple scam versions confusing investors.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos ($XTZ) is trending due to reported success of its Etherlink L2, marked by significant transaction growth and a "Uranium Tokenization Breakthrough," alongside expanded staking accessibility. Community discussion is sharply polarized, with some anticipating a broader altcoin surge and adoption, while others aggressively predict further price declines, citing concerns over dilution and past "greedy" holding.

Ethereum Classic

Ethereum Classic is trending as the community debates its potential for a major comeback and an "alt season," fueled by the anticipated "Clarity Act" and potential FED rate cuts, amidst frustration over its recent underperformance and perceived market manipulation.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

ANKR Network is trending amid overwhelming community frustration and 'scam' accusations, as its persistent price underperformance and declining market rank are compounded by recent discussions suggesting the Neura project may no longer exclusively utilize the ANKR token.

statis crypto Watchlist

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Keefe kept a price target of $3 up from $2.50 on the stock.&nbsp;</li><li>Keefe has concerns around Bitfarms's rising leverage and elevated capex.&nbsp;</li><li>The firm said it does not expect a leasing agreement to materialize for BITF until the second half of 2026.</li></ul><p>Shares of Bitfarms were down more than 1% during after hours of trading on Monday after an analyst raised liquidity concerns for the firm.&nbsp;</p><p>Shares in the company closed down 5.5% on Monday.&nbsp;</p><h2 class="st-heading-2">Liquidity Risks</h2><p>Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’ with a price target of $3, up from $2.50.&nbsp;</p><p>The firm said it does not expect a leasing agreement to materialize for the company until the second half of 2026. The stock already discounts a Sharon deal, said Keefe, which also has concerns around Bitfarms's rising leverage and elevated capex.&nbsp;</p><p>Keefe said it would get more constructive on the shares with greater clarity on the company's liquidity and 2026 capex.</p><h2 class="st-heading-2">Capital Raises</h2><p>Bitfarms in October had said that it has closed its offering of $588 million aggregate principal amount of 1.375% convertible senior notes due 2031. It said that Interest coupon will be payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2026.</p><p>Bitfarms had also converted a private debt facility for up to $300 million from Macquarie Group’s Commodities and Global Markets business, to an up to $300 million project-specific financing facility for the development of its data center campus in Panther Creek, Pennsylvania.</p><h2 class="st-heading-2">AI Data Center Push</h2><p>Bitfarm in 2024 had entered into the definitive lease agreement and assumed control of its newest data center in Sharon, Pennsylvania, initially announced on June 13, 2024.</p><p>This site represented Bitfarms’ first mega-site in the U.S. with access to up to 120 MW.&nbsp;</p><p>Bitfarms has planned to wind down its Bitcoin mining operations by 2027, and its transition will begin with its 18-megawatt site in Washington State.</p><h2 class="st-heading-2">LatAm Exit Deal</h2><p>BITF earlier in the month said it has entered into a share purchase agreement to sell its 70 MW site in Paso Pe, Paraguay, to the Sympatheia Power Fund (SPF), a crypto infrastructure fund managed by Singapore-based Hawksburn Capital.</p><p>The deal was valued at $30 million. Bitfarms would receive $9 million in cash upon closing, expected in Q1 2026, and up to $21 million over 10 months following closing, based on certain payment milestones, it had stated.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment around BITF trended in ‘bearish’ territory amid ‘low’ message volume.</p><p>Shares in the company have risen 65% over the past 12 months.&nbsp;<br>&nbsp;</p>

In this photo illustration, the Bitfarms Ltd logo is seen on a smartphone screen. 

Why Bitfarms Stock Is Down After Hours?

Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’. 

Equity

Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’. 


<ul class="summary-bullets"><li>Reuters noted that oral Wegovy’s debut is stronger than observed with Novo’s injectable Wegovy or its rival Eli Lilly and Company’s Zepbound.&nbsp;</li><li>Novo’s rival Lilly, meanwhile, is looking forward to getting FDA approval for its oral obesity drug Orforglipron by April.</li></ul><p>Danish drugmaker Novo Nordisk’s (NVO) Wegovy pill reportedly hit over 18,000 U.S. prescriptions in the first full week after its launch, marking a strong start for the oral weight-loss pill. &nbsp;</p><p>Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novos-wegovy-pill-tracks-18410-prescriptions-first-full-week-since-launch-2026-01-23/">reported</a> on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16. As per the report, this is a stronger debut than observed with Novo’s injectable Wegovy or its rival Eli Lilly and Company’s Zepbound.</p><p>Last week, it was reported that the Wegovy pill hit 3,071 U.S. prescriptions in just the first four days after its launch on Jan 5.</p><p>NVO shares traded marginally in the green on Friday at the time of writing.</p><h2 class="st-heading-2">Wegovy Pill Approval</h2><p>Oral obesity pills are expected to be the next major innovation in the obesity market, doing away with needles and offering customers more flexibility and ease.</p><p>The U.S. Food and Drug Administration (FDA) approved the Wegovy pill to reduce body weight and maintain weight reduction for a longer term in December.</p><p>The Wegovy pill is now the first FDA-approved oral GLP-1 class drug for weight management and marks a crucial step forward for the company in its ongoing efforts to protect market share from rival Eli Lilly, whose injectable GLP-1 drug Zepbound is fast taking over Wegovy’s market dominance. The company launched the Wegovy pill earlier this month, starting at $149 a month.</p><p>Novo’s rival Lilly, meanwhile, is looking forward to getting FDA approval for its oral obesity drug Orforglipron by April. Novo now has a few months’ head start against Lilly to cement its customer base.</p><p>On Thursday, Goldman Sachs raised its price target on Novo Nordisk to DKK 436 from DKK 352 while keeping a ‘Buy’ rating on the shares. The firm believes investor focus in the first half of 2026 will be the launch for Novo's Wegovy pill. The weight loss pill should contribute to positive earnings momentum in the near term, the analyst told investors, as per TheFly.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVO stock stayed within the ‘bullish’ territory, while message volume fell from ‘high’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/NVO">NVO shares</a> have fallen 23% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/bhc-stock-plummets-on-failed-liver-cirrhosis-trial/cmyRgOmR4gz">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week

Reuters reported on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16.

<ul class="summary-bullets"><li>CEO Thomas J. Appio said that the company is “disappointed in the results.”</li><li>The experimental therapy, however, was safe and well-tolerated, the company said.</li><li>Rifaximin is already approved in the U.S. and marketed as Xifaxan.</li></ul><p>Shares of Bausch Health Companies Inc. (BHC) fell 10% on Friday after the company said that its late-stage program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis failed to meet its primary goal.</p><p>The clinical program <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bauschhealth.com/news-releases/2026/01-23-2026-124516159">evaluated</a> rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes. The program consisted of two global trials involving more than 1000 patients.</p><p>Hepatic encephalopathy is a serious brain dysfunction caused by liver failure, where the liver can't remove toxins from the blood, allowing them to build up and affect the brain, causing confusion, personality changes, slurred speech, and lethargy, potentially leading to coma.</p><h2 class="st-heading-2">Executive Takeaway</h2><p>CEO Thomas J. Appio said that the company is “disappointed in the results.” The experimental therapy, however, was safe and well-tolerated, the company said.</p><p>“We are currently reviewing the full dataset to determine potential new development opportunities," he said while adding that the company remains committed to bringing new treatments to patients across hepatology and other therapeutic areas.</p><p>Rifaximin is already approved in the U.S. and marketed as Xifaxan which is slated to lose exclusivity in 2028. The recent trials were evaluating a new variant of the compound.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around BHC stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘high’ to ‘extremely high’ levels.</p><p>A Stocktwits user expressed anticipation for the company’s quarterly report in February, saying the company “lost &nbsp;a &nbsp;Battle but not &nbsp;the &nbsp;war.”</p><p><stembedurl>https://www.stocktwits.com/Valmaro/message/642700352</stembedurl></p><p>Another user, however, opined that the trial failure is “a serious blow” to the company’s future prospects.</p><p><stembedurl>https://www.stocktwits.com/Contrarian_Dan/message/642693387</stembedurl></p><p><a href="https://stocktwits.com/symbol/BHC">BHC stock</a> has dropped 24% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-market-share-dives-in-ev-stronghold-california-in-2025-paving-way-for-asian-rivals-growth/cmUCgvWR4X8">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration, the Bausch Health logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.

<ul class="summary-bullets"><li>Novo and Aspect have been collaborating since 2023 to develop cellular medicines.</li><li>Under the deal, Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk and will now lead their development.&nbsp;</li><li>Novo, in turn, will make an additional equity investment in Aspect and provide research funding.</li></ul><p>Danish drugmaker Novo Nordisk (NVO) said on Tuesday that it is looking to develop new medicines for diabetes as part of its new partnership with Canadian biotech firm Aspect Biosystems.</p><p>Novo and Aspect have been collaborating since 2023 to develop cellular medicines. The companies <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916478">said</a> that the new partnership phase builds on the momentum achieved in the existing collaboration.</p><h2 class="st-heading-2">Deal Terms</h2><p>Under the deal, Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk. This refers to technology allowing for making insulin-producing cells from stem cells for diabetes treatment and modifying cells to evade the immune system, thereby avoiding immune rejection. The privately-held company will now lead its development, manufacturing and commercialisation.</p><p>Novo, in turn, will make an additional equity investment in Aspect and provide research funding. It will also retain rights to expand its role in late-stage development and commercialisation as well. &nbsp;</p><p>Novo Nordisk will be eligible to receive royalties and milestone payments on future product sales from Aspect. However, the companies didn’t provide the financial terms of the agreement.</p><h2 class="st-heading-2">Novo On Lookout For More</h2><p>Last week, Novo said it is on the lookout for merger and acquisition deals to boost its drug portfolio.</p><p>Novo’s CEO Mike Doustdar said during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets, and companies that are complementary to its portfolio. Doustdar said that the company can afford any amount for an asset, provided it is worth it.</p><p>Novo’s best-selling drugs now include Wegovy and Ozempic for weight loss and diabetes, respectively.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVO stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/NVO">NVO shares</a> have fallen 25% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lululemon-stock-slips-after-reportedly-removing-see-through-leggings-from-website/cmUuHw8R4OO">Lululemon Stock Slips 6% After Reportedly Removing “See-Through” Leggings From Website</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic

Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.

<ul class="summary-bullets"><li>While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival.&nbsp;</li><li>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma.</li><li>The company said it now intends to engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie.</li></ul><p><br>Genmab A/S (GMAB) said on Friday that its late-stage trial evaluating drug Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.</p><p>While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/16/3220513/0/en/Genmab-Announces-Topline-Results-for-Epcoritamab-DuoBody-CD3xCD20-from-Phase-3-EPCORE-DLBCL-1-Trial-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL.html">said.</a> While progression-free survival represents the time a patient lives with cancer without it getting worse or dying, overall survival is the length of time from diagnosis or treatment start until death from any cause.</p><h2 class="st-heading-2">Study Details</h2><p>Genmab enrolled 483 patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma in the trial who had undergone at least one prior line of therapy. These patients were ineligible for high-dose chemotherapy, the company said.</p><p>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma, a blood cancer involving rapid growth of large B-lymphocytes in the lymphatic system, lymph nodes, and other organs, often presenting as fast-growing masses or swollen nodes with symptoms like fever, night sweats, and weight loss. According to Genmab, there are approximately 25,000 new cases of DLBCL diagnosed each year in the U.S.</p><p>The company said it intends to now engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie. Epcoritamab, being co-developed by Genmab and AbbVie, is already approved in several countries for the treatment of certain lymphomas.</p><p>Shares of GMAB fell 5% at the time of writing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around GMAB stock stayed within the ‘bearish’ territory coupled with ‘high’ message volume.</p><p>Meanwhile, sentiment around ABBV shares rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.</p><p>A Stocktwits user sees GMAB stock plummet down to $20 from current levels.</p><p><stembedurl>https://www.stocktwits.com/nopumpdump/message/642093162</stembedurl></p><p><a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> has gained 51% over the past 12 months while <a href="https://stocktwits.com/symbol/ABBV">ABBV shares</a> added 24%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvo-shares-rise-on-strong-kickstart-for-wegoy-pill-in-us/cmUlCCgR4Bq">NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Genmab logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said.

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory diffuse large B-cell lymphoma, the company said.


<ul class="summary-bullets"><li>If approved, Ianalumab could become the first targeted treatment for Sjögren’s disease.&nbsp;</li><li>The Breakthrough Therapy designation was granted to Novartis on the basis of clinical evidence supporting the drug’s potential.</li><li>In Novartis’ late-stage trials evaluating the efficacy and safety of Ianalumab in patients with Sjögren’s disease, the drug delivered a clinically meaningful benefit.</li></ul><p>Shares of Novartis (NVS) rose 1% on Friday after the U.S. Food and Drug Administration granted its drug Ianalumab a breakthrough therapy designation in the treatment of Sjögren’s disease.</p><p>Sjögren’s disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body. It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.</p><p>According to Novartis, 50% of people with Sjögren’s are undiagnosed, though it is the second-most prevalent rheumatic autoimmune disease.</p><p>Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval. If approved, it could become the first targeted treatment for Sjögren’s disease, as per Novartis.</p><h2 class="st-heading-2">The Designation</h2><p>The Breakthrough Therapy designation, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-sjogrens-disease">granted</a> to Novartis on the basis of clinical evidence supporting the drug’s potential, is intended to expedite the review of medicines that treat a serious or life-threatening condition. Ianalumab was previously awarded the FDA’s Fast Track designation in 2016.</p><p>In Novartis’ late-stage trials that evaluated the efficacy and safety of Ianalumab in patients with Sjögren’s disease, the drug delivered a clinically meaningful benefit, showing improvement in disease activity and reductions in patient burden. Further, the drug demonstrated a favorable safety profile with an overall incidence of adverse events comparable to placebo.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVS stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/NVS">NVS stock</a> has gained nearly 48% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvo-shares-rise-on-strong-kickstart-for-wegoy-pill-in-us/cmUlCCgR4Bq">NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment

Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval.

<ul class="summary-bullets"><li>The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment.</li><li>Separately, AstraZeneca announced that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of lung cancer.</li></ul><p>Pharmaceutical giant AstraZeneca (AZN) has purchased Boston-based biomedical AI company Modella AI for an undisclosed sum, according to a statement from the startup on Tuesday.</p><p>Modella <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260113561240/en/Modella-AI-Announces-Acquisition-by-AstraZeneca-to-Advance-AI-Driven-Oncology-RD-at-Global-Scale">said</a> that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.</p><p>The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment. This would allow for the generation of new insights and allow for greater automation across workflows, the company said.</p><p>Shares of AZN traded marginally in the green at the time of writing.</p><h2 class="st-heading-2">Partnership To Acquisition</h2><p>Modella announced a multi-year deal with AstraZeneca in 2025 aimed at integrating its generative and agentic AI platform into AstraZeneca’s oncology research and development organization.</p><p>The collaboration was aimed at supporting efforts to accelerate clinical development and enhancing biomarker discovery.</p><h2 class="st-heading-2">First Patient Dosing In New Late-Stage Trial</h2><p>Separately, AstraZeneca announced earlier on Tuesday that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of locally advanced or metastatic nonsquamous non-small cell lung cancer. Lung cancer is the most common cancer globally.</p><p>Datroway, meanwhile, is a cancer drug jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around AZN stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.</p><p>A Stocktwits user opined that AstraZeneca must try to acquire smaller drugmaker Omeros Corp.</p><p><stembedurl>https://www.stocktwits.com/resq1/message/641646825</stembedurl></p><p><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> has gained 43% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fund-manager-flags-concerns-about-tesla-dwindling-delivery-numbers-high-pe-ratio/cmUXXNkR4Ia">Fund Manager Flags Concerns About Tesla’s Dwindling Delivery Numbers, Notes High P/E Ratio</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio. 

<ul class="summary-bullets"><li>The decision was reportedly a result of waning customer demand and the need to focus on “more competitive electrified solutions, including hybrid and range‑extended vehicles.”&nbsp;</li><li>A Jeep spokesperson confirmed to CNBC that the brand will, however, continue to offer all-electric SUVs.</li><li>In November, Stellantis recalled 320,065 Jeep PHEVs citing fire risk.</li></ul><p>Automaker Stellantis NV (STLA) is reportedly scrapping its Jeep and Chrysler plug-in hybrid electric vehicles in North America as EV demand softens. &nbsp;</p><p>CNBC <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/01/09/stellantis-scraps-jeep-chrysler-phevs-amid-ev-slowdown-recall.html">reported</a> on Friday, citing a company spokesperson, that the company has decided to end production of the plug-in hybrid Jeep Wrangler, Jeep Grand Cherokee and Chrysler Pacifica starting with the 2026 model year. The decision was reportedly a result of waning customer demand and the need to focus on “more competitive electrified solutions, including hybrid and range‑extended vehicles.”</p><p>A Jeep spokesperson confirmed to CNBC that the brand will, however, continue to offer all-electric SUVs.</p><p>STLA shares dropped 2% at the time of writing.</p><h2 class="st-heading-2">Stellantis’s PHEV efforts</h2><p>PHEVs, or Plug-in Hybrid Electric Vehicles, are vehicles with both an electric motor and a traditional gasoline engine that can be charged externally (plugged in) for electric-only range, then seamlessly switch to the gas engine for longer trips.</p><p>Chrysler introduced its PHEV minivan in 2016 and Jeep brand followed with its Wrangler PHEV in 2020 and its Grand Cherokee PHEV in 2021.</p><p>Stellantis did not immediately respond to Stocktwits's request for comment.</p><h2 class="st-heading-2">Sales In US</h2><p>Stellantis said earlier this week that it sold 332,321 vehicles in the fourth quarter, marking a second consecutive quarter of sales increase.</p><p>In October, Stellantis announced a $13 billion investment over four years to grow its business in the U.S. The company is looking to ramp up production by half with the investment and roll out five new vehicles and 19 product refreshes.</p><p>However, in November, Stellantis also <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-recalls-over-320000-jeep-plug-in-hybrids-in-us-over-fire-risk/cL28S1PR36n">recalled</a> 320,065 Jeep PHEVs citing fire risk, including certain model year 2020- 2025 Jeep Wrangler 4Xe and model year 2022-2026 Grand Cherokee 4Xe plug-in hybrid vehicles. The vehicles in the recall may have been built with a high-voltage battery pack manufactured using cells that are susceptible to separator damage, the National Highway Traffic Safety Administration (NHTSA) said. &nbsp;</p><h2 class="st-heading-2">Autonomy Push</h2><p>Separately, Stellantis announced on Friday that it has entered a partnership with Europe’s mobility platform Bolt to explore the development of driverless autonomous vehicles for commercial operations across the region.</p><p>The collaboration would combine Stellantis’ AV-ready platforms with Bolt’s mobility network.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around STLA &nbsp;stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/STLA">STLA stock</a> has lost 13% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-falls-for-fourth-straight-session/cmU2FjBR4dH">SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

General view of Stellantis logo on the new Hybrid and PHEV Vehicles Stellantis Group eDCT Assembly Plant on April 10, 2024, in Turin, Italy. 

Stellantis Stock Drops As It Reportedly Scraps Jeep and Chrysler Plug-In Hybrid Vehicles In US

CNBC reported on Friday, citing a company spokesperson, that the company has decided to end production of the plug-in hybrid Jeep Wrangler, Jeep Grand Cherokee, and Chrysler Pacifica starting with the 2026 model year.

<ul class="summary-bullets"><li>The market is now looking forward to an executive order from President Trump directing federal agencies to reclassify marijuana as a less dangerous drug.</li><li>A Stocktwits user expressed hopes for Trump signing an executive order as early as Wednesday.</li></ul><p>Shares of Tilray Brands (TLRY) soared 31% on Tuesday afternoon as the market gears up for a reclassification of Marijuana.</p><p>Tilray, a producer and distributor of medical and adult-use cannabis, has witnessed volatile trading over the past few days. It closed up 44% on Friday and fell 10% on Monday before rising back again on Tuesday. Shares of the company have gained nearly 79% over the past five days.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around TLRY is trending in the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.</p><figure class="image"><img style="aspect-ratio:623/59;" src="data:image/png;base64,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" width="623" height="59" alt="TLRY’s Sentiment Meter and Message Volume as of 1:41 p.m. ET on December 16, 2025 | Source: Stocktwits"><figcaption>TLRY’s Sentiment Meter and Message Volume as of 1:41 p.m. ET on December 16, 2025 | Source: Stocktwits</figcaption></figure><p>A Stocktwits user expressed hopes for Trump signing an executive order directing federal agencies to reclassify marijuana as a less dangerous drug as early as Wednesday. “Is Tomorrow going to be &nbsp;" Weed"nesday ???,” they wrote.</p><p><stembedurl>https://www.stocktwits.com/Nomoregambling123/message/639326923</stembedurl></p><p>Another believes the stock rising 92% to 115% from current levels is “very doable.” The user sees the stock hitting as high as $28 but added that it is “pure speculation at this point.”</p><p><stembedurl>https://www.stocktwits.com/Beto_365/message/639324734</stembedurl></p><h2 class="st-heading-2">Marijuana Reclassification Hopes</h2><p>Trump first hinted at reclassifying marijuana as a less dangerous drug in August. On Wednesday, Trump reportedly discussed the plan with House Speaker Mike Johnson, a Republican, in a call that also included marijuana industry executives, Health Secretary Robert F. Kennedy Jr., and CMS chief Mehmet Oz.</p><p>The president is expected to seek to ease access to the drug through an upcoming executive order that directs federal agencies to pursue reclassification, the Washington Post reported on Thursday, citing unnamed sources.</p><p>On Friday, CNBC <a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-sndl-soar-on-hopes-trump-will-reclassify-marijuana-on-monday/cLICDZhRE8W">reported</a> that an executive order could come as soon as Monday, causing a significant surge in cannabis stocks during the Friday trading session. However, the rally didn't hold on Monday as investors cashed in on the Friday gains.</p><p>While the executive order didn’t arrive on Monday, Trump said during a Mexican Border Defense medal presentation at the White House in Washington, DC, that he is “strongly” looking at an executive order directing federal agencies to reclassify marijuana/</p><p>"We are considering that. Because a lot of people want to see it," Trump <a href="https://stocktwits.com/news-articles/markets/equity/cannabis-stocks-lose-their-high-as-profit-taking-kicks-in-despite-trumps-reclassification-talk/cLe4j1YREoD">said</a>. "The reclassification, because it leads to tremendous amounts of research that can’t be done unless you reclassify. So we are looking at that very strongly."</p><h2 class="st-heading-2">Tilray CEO Echoes Optimism</h2><p>Tilray CEO Irwin Simon also highlighted in October that the regulatory environment in the industry is “poised for meaningful evolution.”</p><p>Marijuana remains a Schedule I drug under federal law — the same category as heroin and LSD — a classification reserved for substances deemed to have high abuse potential and no accepted medical use.</p><p>Trump is expected to classify marijuana as a Schedule III substance, indicating that it has a lesser potential for abuse and is allowed for use in specific medical treatments, but can also create risks of physical or psychological dependence.</p><p>Other Schedule III drugs include Tylenol with codeine, as well as specific steroid and hormone treatments.</p><h2 class="st-heading-2">Expert Take</h2><p>According to data from Koyfin, the average price target on Tilray is $16.17, presenting a potential upside of over 18% from current trading levels. Of the nine analysts covering the stock, six rate it a ‘Hold’ while three rate it ‘Buy’ or higher.</p><p><a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> is up 19% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-stock-on-track-for-worst-day-in-over-8-months-as-bofa-flags-faster-covid-19-product-errosion/cLeJK4YREpe">Pfizer Stock On-Track For Worst Day In Over 8 Months As BofA Flags Faster Covid-19 Product Erosion</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the logo of a Canadian pharmaceutical and cannabis company, Tilray, is seen on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Tilray Stock On Track For Near 2-Month High As 'Weednesday' Buzz Builds Around Trump Cannabis Order — Retail Eyes Massive Upside

Tilray, a producer and distributor of medical and adult-use cannabis, has witnessed volatile trading over the past few days.

<ul class="summary-bullets"><li>The CEO said that the company received 50,000 orders for the pickup trucks incorporating its reintroduced Hemi V8 engine.&nbsp;</li><li>The company is also looking to relaunch the Jeep Cherokee to the end of December, featuring a a hybrid engine.</li><li>Filosa sees hybrid being one of the favorite powertrains in the U.S.</li></ul><p>Stellantis (STLA) CEO Antonio Filosa said on Thursday that the company envisions ‘highly sustainable’ demand growth with the launch of new engines and vehicle models as he seeks to claw back market share.</p><p>The CEO said that the company received 50,000 orders for the pickup trucks incorporating its reintroduced Hemi V8 engine.</p><p>Stellantis had previously phased out the engine and reintroduced it in pickup trucks in the third quarter (Q3). The CEO said at the Goldman Sachs Industrial &amp; Auto Conference on Thursday that the company delivered 10,000 v8-equipped Hemi engine RAM vehicles in Q3 and expects to ship another 20,000 in the fourth quarter.</p><h2 class="st-heading-2">Other Launches</h2><p>The company is also looking to relaunch the Jeep Cherokee by the end of December, featuring &nbsp;a hybrid engine. It is also eyeing the launch of a new Dodge Charger with an internal combustion engine.</p><p>“So we are launching hybrid because we truly believe that hybrid is going to be one of the favorite powertrains in the U.S.,” Filosa said on Thursday. The company expects its sequence of product launches to spark volume growth that is “highly sustainable and progressively better quarter by quarter.”</p><p>“Through the end of November, we are on track on our guidance,” Filosa said about the company’s profitability expectations. The CEO also highlighted that the company’s execution is improving with more product launches following promised timelines.</p><h2 class="st-heading-2">Tariff Impact</h2><p>The CEO highlighted that U.S. tariffs are getting stable and the company is looking to offset the impact of the Trump administration’s tariffs by onshoring production.</p><p>In October, Stellantis committed $13 billion to expand its US operations over the next four years. The investment will support the launch of five new vehicles, the company then said.</p><h2 class="st-heading-2">Filosa Attempts Major Pivot</h2><p>Stellantis <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-selects-antonio-filosa-as-new-ceo/ch0oL02Rbs3">appointed</a> Filosa as CEO in May after its previous chief executive, Carlos Tavares, stepped down in December 2024.</p><p>In October, the company reported a 13% growth in Q3 revenue to €37.2 billion ($43.35 billion) owing to a 13% growth in consolidated shipments to 1.3 million units.</p><p>“As we continue to implement important strategic changes in order to provide our customers with greater freedom of choice, we have seen positive sequential progress and solid year-over-year performance in Q3, marked by the return of top-line growth. This is encouraging and we are continuing to build on these gains,” Filosa then said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">Stellantis</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.</p><p>The stock is down by 9% this year and by about 7% over the past 12 months.</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pepsico-close-to-striking-settlement-with-activist-giant-elliott-after-4-billion-push-for-change/cLIi4iXREj1">PepsiCo Is Close To Striking A Settlement With Activist Giant Elliott After Its $4B Push For Change</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

New Ram vehicles sit on a Dodge Chrysler-Jeep Ram dealership's lot on October 03, 2023 in Miami, Florida. (Photo by Joe Raedle/Getty Images)

Stellantis CEO Says New Engine, Vehicle Models Will Drive ‘Progressively Better’ Demand 

Filosa said that the company is on track on its full year guidance through the end of November. 

DFAX
Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DFAX News

DFAXDimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF